Which antibiotics should be avoided and which are preferred for treating infections caused by organisms that express basal (constitutive) AmpC beta‑lactamase, such as Enterobacter species, Citrobacter species, Serratia species, and certain Pseudomonas aeruginosa strains?

Antibiotic Selection for Organisms with Basal AmpC β-Lactamase Production

Antibiotics to Avoid

Organisms with constitutive (basal) AmpC β-lactamase production—including Enterobacter species, Citrobacter freundii, Serratia marcescens, and certain Pseudomonas aeruginosa strains—are intrinsically resistant to amoxicillin-clavulanate, first-generation cephalosporins (e.g., cefazolin), and second-generation cephalosporins (e.g., cefoxitin, cefuroxime) due to hydrolysis by the AmpC enzyme. 1, 2, 3

Specific Agents to Avoid:

• Amoxicillin-clavulanate: The β-lactamase inhibitor clavulanate does NOT inhibit AmpC enzymes, rendering this combination ineffective 2, 3
• First-generation cephalosporins (cefazolin, cephalexin): Excellent substrates for AmpC hydrolysis 1, 3
• Second-generation cephalosporins (cefoxitin, cefuroxime, cefotetan): Also hydrolyzed by AmpC despite being cephamycins 1, 3
• Third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime): While organisms may initially appear susceptible in vitro, these agents are poor inducers but good substrates for AmpC, leading to selection of derepressed mutants during therapy with subsequent treatment failure 2, 4, 3
• Piperacillin-tazobactam: Tazobactam does not inhibit AmpC enzymes; this combination is hydrolyzed when AmpC is overproduced 2, 4, 3

Critical Pitfall:

The most dangerous scenario occurs with inducible chromosomal AmpC producers (Enterobacter cloacae complex, Klebsiella aerogenes, Citrobacter freundii): isolates may test susceptible to third-generation cephalosporins initially, but exposure to these agents during treatment selects for derepressed mutants that constitutively overproduce AmpC, causing clinical failure mid-therapy 2, 4, 3

---

Preferred Antibiotics

First-Line Options for Severe Infections:

Carbapenems (meropenem, imipenem, doripenem) are the gold standard for serious bloodstream infections, pneumonia, or intra-abdominal infections caused by AmpC producers, particularly when adequate source control cannot be achieved. 1, 2

• Meropenem or imipenem: Recommended for severe infections, septic shock, or high bacterial inoculum (e.g., ventilator-associated pneumonia, undrainable abscesses) 1, 2
• Ertapenem: May be used for bloodstream infections without septic shock or for community-acquired infections with suspected AmpC producers 1
• Carbapenems remain stable against AmpC hydrolysis and prevent emergence of resistance during therapy 1, 3

Carbapenem-Sparing Alternative:

Cefepime is a well-supported carbapenem-sparing option for AmpC-producing Enterobacterales, particularly in clinically stable patients with adequate source control. 2, 5, 6, 4

• Cefepime is a poor inducer of AmpC and is more stable to AmpC hydrolysis than third-generation cephalosporins 2, 4, 3
• A 2024 retrospective cohort study of 270 bloodstream infections showed no difference in mortality between cefepime and carbapenem therapy (OR 0.63,95% CI 0.23-2.11, p=0.36) after excluding ESBL co-producers 5
• A 2013 propensity-matched study of 96 invasive AmpC infections found equivalent 30-day mortality (OR 0.63,95% CI 0.23-2.11, p=0.36) and length of stay between cefepime and meropenem 6
• Use cefepime cautiously in patients with renal impairment or increased susceptibility to neurological adverse events 5

Algorithm for Antibiotic Selection:

For severe infections (septic shock, ICU admission, inadequate source control):

• Use meropenem 1g IV q8h or imipenem 500mg IV q6h as first-line therapy 1, 2

For moderate infections in clinically stable patients with adequate source control:

• Use cefepime 2g IV q8h as a carbapenem-sparing alternative 2, 5, 6, 4
• Ensure isolate is phenotypically negative for ESBL co-production 5

For non-severe complicated urinary tract infections without septic shock:

• Consider aminoglycosides (if active in vitro) for short-duration therapy or IV fosfomycin 1
• Fluoroquinolones may be used if susceptible, though resistance rates are increasing 1

For low-risk, non-severe infections:

• After clinical stability is achieved, de-escalation to oral fluoroquinolones or trimethoprim-sulfamethoxazole (if susceptible) is appropriate stewardship practice 1

---

Special Considerations for Pseudomonas aeruginosa with AmpC:

P. aeruginosa has intrinsic chromosomal AmpC and multiple efflux pumps, conferring resistance to many β-lactams. 1

• Avoid: Amoxicillin-clavulanate, all cephalosporins except ceftazidime and cefepime, ertapenem (no activity) 1
• Preferred agents: Antipseudomonal carbapenems (meropenem, imipenem, doripenem), ceftazidime, cefepime, piperacillin-tazobactam (if susceptible), or fluoroquinolones 1
• Empiric therapy: Use two antipseudomonal agents initially due to high rates of intrinsic resistance; de-escalate to monotherapy once susceptibility is confirmed 1

---

Newer β-Lactam/β-Lactamase Inhibitor Combinations:

Ceftazidime-avibactam and ceftolozane-tazobactam should be reserved for multidrug-resistant organisms and NOT routinely used for AmpC producers to preserve their activity. 1, 7, 8

• Avibactam inhibits AmpC enzymes, restoring ceftazidime activity against AmpC-producing Enterobacterales and Pseudomonas 7, 8
• These agents lack anaerobic coverage; add metronidazole for intra-abdominal or aspiration pneumonia 1, 7, 8
• Reserve for documented carbapenem-resistant organisms or when carbapenems are contraindicated 1, 7

---

Key Stewardship Principles:

• Avoid extended use of third-generation cephalosporins in settings with high AmpC prevalence due to selection pressure for resistance 1, 7
• De-escalation from carbapenems to cefepime or oral agents (based on susceptibility) once clinical stability is achieved reduces carbapenem selection pressure 1, 7
• Adequate source control (drainage of abscesses, removal of infected devices) is essential; without it, even optimal antibiotics may fail 2, 6, 4